The market awaits a cocrystal drug product was the message from the IQPC Cocrystal meeting in Amsterdam on the 21st-22nd September. Although it appears that both Pharma and Biotech industries are actively engaging in cocrystal development, which should be considered as an extension of the solid form landscape, a marketed cocrystal form is yet to be realized.
Legally, cocrystals are thought to be as patentable as per crystalline salt forms i.e. non-obvious, although some ambiguity still exists. Regulators may consider any submission of a cocrystal drug substance on a case by case basis. Process chemists are also getting to grips with the complexities of multi Kg production. There appears no doubt that cocrystals have utility and may offer additional novel routes to formulation and manufacture as well as increased patient benefits. The next few years may proof to be decisive as interest in cocrystals gains pace.
We welcome your comments and/or questions, our Pharmorphix team of experts in Solid State Chemistry will answer your questions.
To learn on how SAFC can help with cocrystalization studies, visit us at CPhI Booth 3B56 Oct 13-15, or click here
